Literature DB >> 23159313

Stanniocalcin 1 is important for poststroke functionality, but dispensable for ischemic tolerance.

A Durukan Tolvanen1, J A Westberg, M Serlachius, A C-M Chang, R R Reddel, L C Andersson, T Tatlisumak.   

Abstract

Stanniocalcin 1 (STC1), originally described as an antihypercalcemic hormone in fish, is highly expressed in differentiated mammalian neurons. Mild hypoxic treatment and focal cerebral ischemia induce upregulation of STC1 in the brain. These findings prompted us to investigate whether STC1 contributes to neuroprotection after ischemia and whether STC1 is required for development of ischemic tolerance. We induced 60 minutes of temporary middle cerebral artery occlusion in wild type (WT) and STC1-deficient mice (STC1(-/-)) with or without prior hypoxic preconditioning (HPC, 8% oxygen for 6 hours followed by reoxygenation for 24 hours). Infarct sizes, neurological scores, and Stc1, Stc2, and Il-6 mRNA brain levels were measured 24 hours after ischemia. Additionally, we examined blood-brain barrier (BBB) integrity (Evans Blue fluorescence) under normal conditions and 0 and 24 hours after hypoxia. STC1(-/-) and WT mice developed brain infarcts of similar size. In both strains, HPC triggered ischemic tolerance with similar reduction in infarct size. However, STC1(-/-) mice had worse neurological scores in both scenarios. HPC induced upregulation of STC1 and STC2 in WT mice and of STC2 in STC1(-/-) mice. Ischemic STC1(-/-) mice showed significantly lower Il-6 mRNA expression than ischemic WT mice. Evans Blue fluorescence levels showed no difference in between WT and STC1(-/-) mice under evaluated conditions, thus BBB integrity is preserved despite STC1 deficiency. STC1 was not crucial for the development of ischemic tolerance triggered by HPC or for preserving BBB integrity but may be involved in functional recovery after stroke.
Copyright © 2012 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23159313     DOI: 10.1016/j.neuroscience.2012.10.062

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  15 in total

1.  STC1 expression is associated with tumor growth and metastasis in breast cancer.

Authors:  Andy C-M Chang; Judy Doherty; Lily I Huschtscha; Richard Redvers; Christina Restall; Roger R Reddel; Robin L Anderson
Journal:  Clin Exp Metastasis       Date:  2014-11-13       Impact factor: 5.150

2.  Depletion of carbonic anhydrase IX abrogates hypoxia-induced overexpression of stanniocalcin-1 in triple negative breast cancer cells.

Authors:  Elīna Zandberga; Pawel Zayakin; Artūrs Ābols; Dārta Pūpola; Pēteris Trapencieris; Aija Linē
Journal:  Cancer Biol Ther       Date:  2017-06-30       Impact factor: 4.742

3.  Cerebrospinal Fluid Stanniocalcin-1 as a Biomarker for Alzheimer's Disease and Other Neurodegenerative Disorders.

Authors:  Pashtun Shahim; Kaj Blennow; Per Johansson; Johan Svensson; Simone Lista; Harald Hampel; Leif Christer Andersson; Henrik Zetterberg
Journal:  Neuromolecular Med       Date:  2016-09-19       Impact factor: 3.843

4.  Stanniocalcin-1 is a Modifier of Oxygen-Induced Retinopathy Severity.

Authors:  Lauren A Dalvin; Mary Elizabeth Hartnett; Colin A Bretz; Cheryl R Hann; Ricky Z Cui; Alan D Marmorstein; David Sheikh-Hamad; Michael P Fautsch; Gavin W Roddy
Journal:  Curr Eye Res       Date:  2019-08-28       Impact factor: 2.424

5.  Long-term photoreceptor rescue in two rodent models of retinitis pigmentosa by adeno-associated virus delivery of Stanniocalcin-1.

Authors:  Gavin W Roddy; Douglas Yasumura; Michael T Matthes; Marcel V Alavi; Sanford L Boye; Robert H Rosa; Michael P Fautsch; William W Hauswirth; Matthew M LaVail
Journal:  Exp Eye Res       Date:  2017-09-30       Impact factor: 3.467

6.  Intravitreal Stanniocalcin-1 Enhances New Blood Vessel Growth in a Rat Model of Laser-Induced Choroidal Neovascularization.

Authors:  Min Zhao; Wankun Xie; Shu-Huai Tsai; Travis W Hein; Brent A Rocke; Lih Kuo; Robert H Rosa
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-02-01       Impact factor: 4.799

7.  Stanniocalcin-1 Is an Ocular Hypotensive Agent and a Downstream Effector Molecule That Is Necessary for the Intraocular Pressure-Lowering Effects of Latanoprost.

Authors:  Gavin W Roddy; Kimberly B Viker; Nelson S Winkler; Cindy K Bahler; Bradley H Holman; David Sheikh-Hamad; Uttio Roy Chowdhury; W Daniel Stamer; Michael P Fautsch
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-05-01       Impact factor: 4.799

8.  Characteristics of a rat model of an open craniocerebral injury at simulated high altitude.

Authors:  An-Yong Yu; Quan-Hong Xu; Sheng-Li Hu; Fei Li; Yu-Jie Chen; Yi Yin; Gang Zhu; Jiang-Kai Lin; Hua Feng
Journal:  Neuroreport       Date:  2014-11-12       Impact factor: 1.837

9.  Stanniocalcin-1 Protects a Mouse Model from Renal Ischemia-Reperfusion Injury by Affecting ROS-Mediated Multiple Signaling Pathways.

Authors:  Dajun Liu; Huiping Shang; Ying Liu
Journal:  Int J Mol Sci       Date:  2016-07-12       Impact factor: 5.923

10.  Stanniocalcin 1 Inhibits the Inflammatory Response in Microglia and Protects Against Sepsis-Associated Encephalopathy.

Authors:  Sandra Bonfante; Larissa Joaquim; Maria Eduarda Fileti; Amanda Della Giustina; Mariana Pereira de Souza Goldim; Lucinéia Gainski Danielski; Evandro Cittadin; Raquel Jaconi De Carli; Bianca Xavier de Farias; Nicole Alessandra Engel; Naiana da Rosa; Jucélia Jeremias Fortunato; Vijayasree Giridharan; Giselli Scaini; Gislaine Tezza Rezin; Jaqueline Generoso; Rafael Mariano de Bitencourt; Silvia Terra; Tatiana Barichello; Fabricia Petronilho
Journal:  Neurotox Res       Date:  2020-10-06       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.